1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,168 | 0,191 | 28.06. | |
| 0,169 | 0,188 | 27.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06. | BRII-B (02137): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 03.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 3, 2025 AND CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.05. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
| 28.04. | BRII-B (02137): CLARIFICATION ANNOUNCEMENT (1) CHANGE OF DATE OF ANNUAL GENERAL MEETING; AND (2) CHANGE OF CLOSURE OF THE REGISTER OF MEMBERS | 1 | HKEx | ||
| 25.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 25.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 25.04. | BRII-B (02137): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 25.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 25.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 25.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
| 25.04. | BRII-B (02137): 2024 ANNUAL REPORT | - | HKEx | ||
| 07.04. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 30.03. | Brii Biosciences Limited: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | 54 | PR Newswire | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and... ► Artikel lesen | |
| 21.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results | 180 | PR Newswire |
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Data... ► Artikel lesen | |
| 21.03. | BRII-B (02137): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE IN USE OF PROCEEDS | 1 | HKEx | ||
| 21.03. | BRII-B (02137): NOTIFICATION OF 2024 PFIC STATUS | - | HKEx | ||
| 10.03. | BRII-B (02137): DATE OF BOARD MEETING | - | HKEx | ||
| 15.01. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
| 10.01. | BRII-B (02137): SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO NOMINEE DESIGNATION AGREEMENT | 1 | HKEx | ||
| 10.01. | BRII-B (02137): CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
| ILLUMINA | 80,30 | -0,91 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
| NANOREPRO | 1,645 | -0,30 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
| BRAIN BIOTECH | 1,860 | -3,38 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,355 | +3,50 % | Neuer Biotech-Boom entfacht: Evotec, BioNxt, Bayer, Novo Nordisk und Formycon vor dem nächsten Kursschub? | Die Biotechnologie-Branche erlebt derzeit eine bemerkenswerte Renaissance. Innovationen in der personalisierten Medizin, Fortschritte bei mRNA-Technologien sowie neue Therapieansätze gegen Krebs und... ► Artikel lesen | |
| INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 2,635 | +1,54 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CYTODYN | 0,258 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer | VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
| TME PHARMA | 0,072 | -4,99 % | TME Pharma N.V.: TME Pharma Provides Results of Final Exercise of Warrants Z | 1,948 Warrants Z were exercised resulting in the issuance of 2,435 new ordinary shares
Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company... ► Artikel lesen | |
| IMMUNIC | 0,602 | +1,01 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,250 | +1,81 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,470 | +1,52 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen |
BRII BIOSCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,177 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.